MoneyWorks4Me

Samrat Pharmachem - Quaterly Results

10 Feb 2022 Evaluate
The Total revenue for the quarter ended December 2021 of  Rs. 555.78 millions remain, more or less, the same.The Total revenue for the quarter ended December 2021 of  Rs. 64.47  millions  grew by 319.45% from Rs. 15.37 millions.OP of the company witnessed a marginal growth to 88.36 millions from 25.44 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202112 202012 % Var 202112 202012 % Var 202103 202003 % Var
Sales 555.78 549.41 1.16 1618.90 1317.05 22.92 1790.18 1374.53 30.24
Other Income 0.00 0.00 0.00 2.27 0.42 440.48 4.63 5.72 -19.06
PBIDT 88.36 25.44 247.33 146.39 68.63 113.30 91.31 72.02 26.78
Interest 1.26 3.62 -65.19 5.07 11.02 -53.99 12.77 9.78 30.57
PBDT 87.10 21.82 299.18 141.32 57.61 145.30 78.36 62.12 26.14
Depreciation 1.51 1.27 18.90 4.44 3.58 24.02 4.93 4.26 15.73
PBT 85.59 20.55 316.50 136.88 54.03 153.34 73.43 57.86 26.91
TAX 21.12 5.18 307.72 34.98 16.29 114.73 20.11 15.48 29.91
Deferred Tax -0.04 0.28 -114.29 1.40 3.24 -56.79 2.88 -1.77 -262.71
PAT 64.47 15.37 319.45 101.90 37.74 170.01 53.32 42.38 25.81
Equity 30.90 30.90 0.00 30.90 30.90 0.00 30.90 30.90 0.00
PBIDTM(%) 15.90 4.63 243.35 9.04 5.21 73.53 5.10 5.24 -2.65
Peers
Company Name CMP
Sun Pharma. Inds. 1853.00
Dr. Reddys Labs. 1200.40
Cipla 1404.00
Lupin 2098.00
Zydus Lifesciences 1180.00
View more..